About the Study

Ages Eligible for Study: 18 Years to 85 Years (Adult, Senior); Genders Eligible for Study: All; Accepts Healthy Volunteers: No

Inclusion Criteria

  • Patients confirmed Cushing's syndrome [i.e. ectopic corticotropin syndrome, adrenal adenoma, adrenal carcinoma, ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH), or Primary Pigmented Nodular Adrenal Dysplasia (PPNAD)]
  • For patients on medical treatment for hypercortisolism due to Cushing's syndrome, the washout periods must be completed prior to baseline efficacy assessments.

Exclusion Criteria

  • Patients with Cushing's disease
  • History of hypersensitivity to osilodrostat or to drugs of similar chemical classes
  • History of malignancy of any organ system, treated or untreated, within the past 5 years
  • Patients receiving treatment for within 4 weeks or ≤5 x half-life of the agent (whichever is longer) before first dose of osilodrostat
  • Patients with risk factors for QTc prolongation or Torsade de Pointes
  • Other protocol defined Inclusion/Exclusion may apply.

Study Team

Team Member

Study Coordinator
Team Member

Data Manager
Team Member

Site Manager
Team Member

Lead CRA
Team Member

Principal Investigator

Share this study: